Annals of Surgical Oncology

, Volume 16, Issue 7, pp 1727–1733 | Cite as

Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement

  • Mark P. Callery
  • Kenneth J. Chang
  • Elliot K. Fishman
  • Mark S. Talamonti
  • L. William Traverso
  • David C. LinehanEmail author

Radiographic Imaging

Currently, multidetector computed tomography (CT) with three-dimensional (3-D) reconstruction is the preferred method to diagnose and stage pancreatic cancer. Magnetic resonance imaging and magnetic resonance imaging cholangiopancreatography can also detect primary tumors (hypointense on T1-weighted image) as well as regional and distant metastasis, but no clear advantage over CT has been demonstrated.1Magnetic resonance imaging cholangiopancreatography allows for visualization of the bile duct and pancreatic duct similar to endoscopic retrograde cholangiopancreatography (ERCP) but adds little to the assessment of resectability. The routine use of ERCP for diagnosis is not supported, but therapeutic ERCP may be considered in symptomatic patients with obstructive jaundice (e.g., moderate to severe pruritus) who are awaiting surgery. Endoscopic ultrasound (EUS) may be more sensitive than CT in detecting small tumors and can be useful in patients with obstructive...


Pancreatic Cancer Hepatic Artery Superior Mesenteric Artery National Comprehensive Cancer Network Pancreatic Adenocarcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Reinhold C. Magnetic resonance imaging of the pancreas in 2001. J Gastrointest Surg. 2002;6:133–5PubMedCrossRefGoogle Scholar
  2. 2.
    Ozaki Y, Oguchi K, Hamano H, et al. Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine–18 fluorodeoxyglucose positron emission tomography. J Gastroenterol. 2008;43:144–51PubMedCrossRefGoogle Scholar
  3. 3.
    Heinrich S, Goerres GG, Schäfer M, et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg. 2005;242:235–43PubMedCrossRefGoogle Scholar
  4. 4.
    Bang S, Chung HW, Park SW, et al. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol. 2006;40:923–9PubMedCrossRefGoogle Scholar
  5. 5.
    Goh BKP. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg. 2006;243:709–10.PubMedCrossRefGoogle Scholar
  6. 6.
    McNulty NJ, Francis IR, Platt JF, et al. Multi-detector row helical CT of the pancreas: effect of contrast-enhanced multiphasic imaging on enhancement of the pancreas, peripancreatic vasculature, and pancreatic adenocarcinoma. Radiology. 2001;220:97–102PubMedGoogle Scholar
  7. 7.
    Horton KM, Fishman EK. Adenocarcinoma of the pancreas: CT imaging. Radiol Clin North Am. 2002;40:1263–72PubMedCrossRefGoogle Scholar
  8. 8.
    Megibow AJ, Babb JS, Hecht EM, et al. Evaluation of bowel distention and bowel wall appearance by using neutral oral contrast agent for multi-detector row CT. Radiology. 2006;238:87–95PubMedCrossRefGoogle Scholar
  9. 9.
    Raptopoulos V, Steer ML, Sheiman RG, et al. The use of helical CT and CT angiography to predict vascular involvement from pancreatic cancer: correlation with findings at surgery. AJR Am J Roentgenol. 1997;168:971–7PubMedGoogle Scholar
  10. 10.
    House MG, Yeo CJ, Cameron JL, et al. Predicting resectability of periampullary cancer with three-dimensional computed tomography. J Gastrointest Surg. 2004;8:280–8PubMedCrossRefGoogle Scholar
  11. 11.
    Bronstein YL, Loyer EM, Kaur H, et al. Detection of small pancreatic tumors with multiphasic helical CT. AJR Am J Roentgenol. 2004;182:619–23PubMedGoogle Scholar
  12. 12.
    Lu DS, Reber HA, Krasny RM, Kadell BM, Sayre J. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol. 1997;168:1439–43PubMedGoogle Scholar
  13. 13.
    Chang KJ. EUS-guided fine needle injection (FNI) and anti-tumor therapy. Endoscopy. 2006;38 Suppl 1:S88–93PubMedCrossRefGoogle Scholar
  14. 14.
    Chang KJ. State-of-the-art lecture: endoscopic ultrasound (EUS) and FNA in pancreatico-biliary tumors. Endoscopy. 2006;38(Suppl 1):S56–60PubMedCrossRefGoogle Scholar
  15. 15.
    Boujaoude J. Role of endoscopic ultrasound in diagnosis and therapy of pancreatic adenocarcinoma. World J Gastroenterol. 2007;13:3662–6PubMedGoogle Scholar
  16. 16.
    Jhala NC, Jhala D, Eltoum I, et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy: a powerful tool to obtain samples from small lesions. Cancer. 2004;102:239–46PubMedCrossRefGoogle Scholar
  17. 17.
    Eloubeidi MA, Tamhane A, Varadarajulu S, Wilcox CM. Frequency of major complications after EUS-guided FNA of solid pancreatic masses: a prospective evaluation. Gastrointest Endosc. 2006;63:622–9PubMedCrossRefGoogle Scholar
  18. 18.
    Paquin SC, Gariepy G, Lepanto L, et al. A first report of tumor seeding because of EUS-guided FNA of a pancreatic adenocarcinoma. Gastrointest Endosc. 2005;61:610–1PubMedCrossRefGoogle Scholar
  19. 19.
    Micames C, Jowell PS, White R, et al. Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc. 2003;58:690–5PubMedCrossRefGoogle Scholar
  20. 20.
    Erickson RA, Garza AA. Impact of endoscopic ultrasound on the management and outcome of pancreatic carcinoma. Am J Gastroenterol. 2000;95:2248–54PubMedCrossRefGoogle Scholar
  21. 21.
    Chen VK, Arguedas MR, Kilgore ML, Eloubeidi MA. A cost-minimization analysis of alternative strategies in diagnosing pancreatic cancer. Am J Gastroenterol. 2004;99:2223–34PubMedCrossRefGoogle Scholar
  22. 22.
    National Comprehensive Cancer Network (NCCN). NCCN updates pancreatic adenocarcinoma guidelines. November 26, 2007. Available at: Accessed February 23, 2009
  23. 23.
    Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035–46PubMedCrossRefGoogle Scholar
  24. 24.
    Potter MW, Shah SA, McEnaney P, Chari RS, Callery MP. A critical appraisal of laparoscopic staging in hepatobiliary and pancreatic malignancy. Surg Oncol. 2000;9:103–10PubMedCrossRefGoogle Scholar
  25. 25.
    Stefanidis D, Grove KD, Schwesinger WH, Thomas CR Jr. The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review. Ann Oncol. 2006;17:189–99PubMedCrossRefGoogle Scholar
  26. 26.
    Conlon KC, Dougherty E, Klimstra DS, et al. The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Ann Surg. 1996;223:134–40PubMedCrossRefGoogle Scholar
  27. 27.
    Jimenez RE, Warshaw AL, Rattner DW, et al. Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg. 2000;135:409–14PubMedCrossRefGoogle Scholar
  28. 28.
    Thomson BN, Parks RW, Madhavan KK, Wigmore SJ, Garden OJ. Early specialist repair of biliary injury. Br J Surg. 2006;93:216–20PubMedCrossRefGoogle Scholar
  29. 29.
    Holzman MD, Reintgen KL, Tyler DS, Pappas TN. The role of laparoscopy in the management of suspected pancreatic and periampullary malignancies. J Gastrointest Surg. 1997;1:236–43PubMedCrossRefGoogle Scholar
  30. 30.
    Zamboni GA, Kruskal JB, Vollmer CM, et al. Pancreatic adenocarcinoma: value of multidetector CT angiography in preoperative evaluation. Radiology. 2007;245:770–8PubMedCrossRefGoogle Scholar
  31. 31.
    Pisters PW, Lee JE, Vauthey JN, Charnsangavej C, Evans DB. Laparoscopy in the staging of pancreatic cancer. Br J Surg. 2001;88:325–37PubMedCrossRefGoogle Scholar
  32. 32.
    Vollmer CM, Drebin JA, Middleton WD, et al. Utility of staging laparoscopy in subsets of peripancreatic and biliary malignancies. Ann Surg. 2002;235:1–7PubMedCrossRefGoogle Scholar
  33. 33.
    Karachristos A, Scarmeas N, Hoffman JP. CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg. 2005;9:1286–92PubMedCrossRefGoogle Scholar
  34. 34.
    Liu RC, Traverso LW. Diagnostic laparoscopy improves staging of pancreatic cancer deemed locally unresectable by computed tomography. Surg Endosc. 2005;19:638–42PubMedCrossRefGoogle Scholar
  35. 35.
    Ferrone CR, Haas B, Tang L, et al. The influence of positive peritoneal cytology on survival in patients with pancreatic adenocarcinoma. J Gastrointest Surg. 2006;10:1347–53PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2009

Authors and Affiliations

  • Mark P. Callery
    • 1
  • Kenneth J. Chang
    • 2
  • Elliot K. Fishman
    • 3
  • Mark S. Talamonti
    • 4
  • L. William Traverso
    • 5
  • David C. Linehan
    • 6
    Email author
  1. 1.Department of SurgeryBeth Israel Deaconess Medical CenterBostonUSA
  2. 2.Gastrointestinal Oncology Program, Irvine Medical CenterUniversity of CaliforniaOrangeUSA
  3. 3.Russell H. Morgan Department of Radiology and Radiological ScienceJohns Hopkins University School of MedicineBaltimoreUSA
  4. 4.Department of SurgeryJohns Hopkins University School of MedicineBaltimore USA
  5. 5.Department of General, Vascular and Thoracic SurgeryVirginia Mason ClinicSeattleUSA
  6. 6.Department of SurgeryWashington University School of MedicineSt. LouisUSA

Personalised recommendations